Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 2.08% 24.50 2,577,686 09:34:57
Bid Price Offer Price High Price Low Price Open Price
24.00 25.00 24.75 23.75 24.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.25 -5.60 -3.35 164
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:44 O 41,068 24.3501 GBX

Open Orphan (ORPH) Latest News

More Open Orphan News
Open Orphan Investors    Open Orphan Takeover Rumours

Open Orphan (ORPH) Discussions and Chat

Open Orphan Forums and Chat

Date Time Title Posts
23/1/202117:35open orphan a new beginning 10,926
27/11/202013:06Open Orphan - Big things to come1,285
23/9/202016:01OPEN ORPHAN18
23/9/202015:32Open Orphan - 202014
23/9/202015:27Pharma stock to watch3

Add a New Thread

Open Orphan (ORPH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Open Orphan trades in real-time

Open Orphan (ORPH) Top Chat Posts

DateSubject
23/1/2021
08:20
Open Orphan Daily Update: Open Orphan Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ORPH. The last closing price for Open Orphan was 24p.
Open Orphan Plc has a 4 week average price of 23.50p and a 12 week average price of 20.75p.
The 1 year high share price is 32p while the 1 year low share price is currently 4.78p.
There are currently 667,979,196 shares in issue and the average daily traded volume is 1,645,516 shares. The market capitalisation of Open Orphan Plc is £163,654,903.02.
22/1/2021
01:06
ross k: Taken from Vox Markets, just published earlier today, a reminder of the potential that's not priced in either. Planned DisposalWhen Open Orphan acquired hVIVO in January 2020, hVIVO also came with a number of non-core assets including a 62.6% stake in PrEP Biopharm. However, the new Open Orphan Board and management team are primarily focussed upon cementing its position as a unique CRO and 'world leader vaccine and antiviral testing using human challenge study models, and therefore earmarked all non-core assets for disposal.The options for disposal of this unique asset are exciting, numerous and particularly timely given its mode of action. These options could include a trade sale to a Big-Pharma for cash, reverse the asset into the resurgence of listed SPACs and Cash Shells, or even Spin the asset out into a newly listed entity delivering investors dividends in specie of newly formed companies.In any event, OPRH shareholders would do well to remain on the Shareholder register when this transaction takes place as, whilst the valuation of PrEP Biopharm is currently unknown, with little carrying value on the Open Orphan balance sheet, it should advance the share price accordingly.
19/1/2021
17:33
discojames: Gimmetheloot I think you have totally misunderstood this, this are listing a non-core asset which is currently assigned zero value, not dual-listed ORPH. It shows a complete lack of understanding to think it would make ORPH share price plummet
15/1/2021
11:42
m5: troutisout15 Jan '21 - 11:14 - 10586 of 10587 You can agree or disagree, that's fine. I don't comment a lot on intra day moves, if I do I always finish by saying its the EOD price that I am interested in. Anybody that reads my posts will know that. My post this morning was simple, I have no idea what the fuss is about. I am interested to see if the share price will rise or if will get sold into, hopefully it will not and we can move forward over the next few trading sessions. You say you don't what to speculate about Invesco but you are doing just that. Make your mind up. I have no problem either way, its a BB, that's what happens. When we consolidated last time the fact that Institutions were selling was discussed at length and with CF, who had indeed tried to place some of the shares with other Institutions but was blanked. We also discussed Institutions top slicing. It wasn't an issue and it was reassuring to know the reason for the share price inactivity at that time. When the selling finished we rose. With respect,I will post what I like, you or anyone else can agree or disagree. If it annoys you, use the filter button. People can make their own minds up and should always do their own research.
15/1/2021
11:37
ped2323: Mark, I posted over on L-S-E earlier this week that I’d seen trades earlier this week for 500k and 340k on one day, followed by 500k , 300k and 300k the next day. Almost certainly it is Invesco who are selling off a huge amount of ‘Woodford̵7; tainted assets (inc £60m sale of all IP Group assets just last week). ORPH’s share price also flatlined for a couple of months in the summer when Link sold ORPH’s shares in a Woodford fund to an American fund. They were sold cheaply and the American fund dripped them into the market. CF commented in a presentation that he had approached the American fund to “buy them all at a higher price that market price but they refused”. GLA
13/1/2021
17:26
pogue: SMTM there was a seller at around 6p who CF asked if he could help them dispose of the shares as it was suppressing the share price but they refused and the shares were dripped into the market. Seems like its happening again. I am sure CF will have spoken to the seller, unless he is happy to see the share price suppressed, to see if he can help redistribute the shares.
13/1/2021
16:05
adamb1978: Hello all Going back to the comments on here this morning about profitability and whether the market has digested it already, I'd make a couple related points: - given the FY19 results and 2020 interims were so noisy due to the combination and PF figures etc, there will be a group of investors who are put off and just put OPRH into the 'too hard' pile. I was in that group until recently and it was the newsflow, cash balance and Q4 profitability which convinced me to take a position. But many people won't do so and would want to see a clean set of figures first, which pretty much will be the 2020 FY results - the Q4 profitability won't be picked up by screens etc, and another group of investors will look for profitability in their investments and if a screen doesnt show that for 2020 full year, they won't know ORPH - the market forecasts show turnover going from £9m to £24m, and with the interims only £7m. There will be another set of investors who just won't buy that til the £24m is confirmed by the company None of this makes me nervous though given the above comments about the attractions in the figures. There is also a risk/reward play here in that some of the lack of clarity in the numbers at the moment (which result from it being a newly merged company) results in a discounted share price due to certain investors sitting on the sidelines. If the company can deliver a decent set of 2020 figures then the share price could appreciate markedly from here. I do think though that those 2020 figures and outlook statement are a sufficient condition for the share price moving though. Confirmation that the market expectations for 2020 are broadly right and directional guidance to somethin akin to the 2021 market expectations as they stand today will put the share price into a difference bracket and the 20p-30p range will be long behind this company. All IMO of course! Adam
07/1/2021
21:14
chelsea101: For those unable to open link:- Open Orphan Open Orphan (AIM:ORPH), a contract research organization (CRO), for the testing of vaccines and antivirals, made waves this October with the award of a contract with the UK Government to conduct the world’s first Covid-19 ‘challenge study’. The study, to be conducted by the company’s hVIVO subsidiary, will see, to discover the minimum amount of the virus it takes to develop Covid-19, and thereby help calibrate the future development of the vaccine. The first stage of this project will explore the feasibility of exposing healthy volunteers to the virus: if the research is approved by regulators it will begin early next year with results expected by May. The contract, which has already commenced, could be worth some £10m to hVIVO depending upon the final number of volunteers included in the characterisation study. hVIVO also offers a full range of COVID-19 tests through its COVID Clear programme. The contract offers the prospect of a healthy return on Open Orphan’s investment in hVIVO, which it acquired for £13m in equity in January. The company’s interim results for the six months ended 30 June 2020 stated a cash balance of £14.7m following two successful placings in January and May. An EBITDA loss of £4.1m for H1 2020 was recorded, but the company is targeting near-term profitability in light of its strong pipeline of contracted work. It should be noted Open Orphan has another major subsidiary, Venn Life Sciences, offering drug development consultancy, clinical trial design and execution. Venn’s capabilities include CMC, Non-Clinical, Clinical Development and Regulatory Affairs. Unsurprisingly Open Orphan’s share price has gathered spectacular momentum this year, rising from less than 5p in January to nearly 25p today. Continued uncertainty regarding the UK’s emergence from the pandemic means Open Orphan’s strong run may continue for some time yet.
07/1/2021
07:41
pierre oreilly: Deja vu.Insts selling allowed me to buy in at a cheap price about a year ago. After 2 or 3 weeks after loading up we were all getting concerned about the lack of price increase. Then an rns saying some inst had sold, and off we went. They sold around 5/6p. They probably had no choice due to withdrawals from their funds due to Woodford.Up the price went to 12pish. I posted a similar post to this then. Stuck around 12pish until the selling done. I wondered why the inst seller didn't let the price climb 5p more and then sell, freezing the price temporarily at 17p.So then up it went to the current 26pish. Stuck for a week or 2 or 3 as the inst sales go through. Now there's that several millions been sold and the 6% boundary crossed on monday, so the game given away. (Btw, it's not the inst who rnss the boundary crossing, it's orph, to UK not us regulations).The above is factual to the best of my memory, so now the speculation bit.Invesco crossed 6% on Monday and informed orph of that fact when it happened. They knew they had 2 days before the holding rns hit the market. I expect Invesco sold many more in those two days. I expect they won't sell anymore untill the market absorbs all those and the price reaches the next leg up. Probably 50p judging by the doubling of the price when they had offloaded before. Obviously just my thoughts hopes and genuine expectations which many will disagree with. I think next week orph will be romping up to the next level without an inst seller, hopefully. The technical undervaluation is tough for holders but good for those wanting to buy in at a technically reduced price, just as I did a yearish ago.
06/1/2021
13:18
qackers: Last few paragraphs from Vox market article referred to by Bobsworth in post 10221 Planned Disposal When Open Orphan acquired hVIVO in January 2020, hVIVO also came with a number of non-core assets including a 62.6% stake in PrEP Biopharm. However, the new Open Orphan Board and management team are primarily focussed upon cementing its position as a unique CRO and ‘world leader vaccine and antiviral testing using human challenge study models, and therefore earmarked all non-core assets for disposal. The options for disposal of this unique asset are exciting, numerous and particularly timely given its mode of action. These options could include a trade sale to a Big-Pharma for cash, reverse the asset into the resurgence of listed SPACs and Cash Shells, or even Spin the asset out into a newly listed entity delivering investors dividends in specie of newly formed companies. In any event, OPRH shareholders would do well to remain on the Shareholder register when this transaction takes place as, whilst the valuation of PrEP Biopharm is currently unknown, with little carrying value on the Open Orphan balance sheet, it should advance the share price accordingly.
06/1/2021
10:33
m5: I think CF has had quite a bit of grief about his comments regarding the share price and its been wildly discussed here. The consensus is he should not be talking about price and just get on running the business and carry on doing the great job he is going. The BN is an embarrassment and even the very basics are wrong. If CF continues to mention the price in the future then I will feel uncomfortable to be honest. I certainly would not want a share price that fluctuates that much to be honest. That is a traders delight and that's exactly what I would be doing. The progress continues to be exceptional. There is now I believe a disconnect between price and the value of the business. We certainly don't need any further comments about containment. IMHO. Once the wearables deal drops and the results are out, it will not be possible to keep the share price down as the numbers will speak for themselves.
Open Orphan share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210124 01:03:45